Smarter Utility

 

TMCNet: Sign Up and Be In The Know!! AGRT,AVII,PRGS,LIFE,CNQR,MYL

[December 22, 2009]

Sign Up and Be In The Know!! AGRT,AVII,PRGS,LIFE,CNQR,MYL

(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (OTCBB: AGRT) AGR Tools, Inc., (NASDAQ: AVII) AVI BioPharma, Inc., (NASDAQ: PRGS) Progress Software Corp., (NASDAQ: LIFE) Life Technologies Corporation, (NASDAQ: CNQR) Concur Technologies, Inc., (NASDAQ: MYL) Mylan, Inc.


www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! info@StockMarketingInc.com or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: AGRT - AGR Tools, Inc.) LATEST NEWS!! AGR Expands Distribution Network to Nashville CONROE, TX, Dec 22, 2009 -- AGR Tools, Inc. (OTCBB:AGRT) is pleased to announce that AGR Stone & Tools USA, Inc., with which AGR Tools, Inc. has entered into a binding share exchange agreement, has expanded its distribution network into Nashville and the Middle Tennessee markets. With a population of approximately two million people and a multi-million dollar diamond tool market, the territory serviced by this addition will allow the company to continue increasing its presence in North America. The AGR Stone & Tools USA, Inc. distribution center in this region will be able to service Middle Tennessee's numerous general contractors, granite fabricators, concrete contractors, stonemasons, tile contractors and other construction professionals. The expansion will also position the company to take advantage of the large amount of government infrastructure spending in the state of Tennessee.

AGR Stone & Tools USA, Inc.'s entry into the Tennessee market represents an important step in achieving the expansion objectives the company has outlined for 2009. Its growing list of distribution centers throughout North America now consists of a network of 22 distribution outlets in 15 states and provinces in the United States and Canada.

As the only major manufacturer of diamond tools that markets and distributes its products directly to customers, AGR Stone & Tools USA, Inc. has a major advantage over its competition. By selling directly, its goal is to control a quarter of the approximately $8 billion North American diamond tool market. "As our distribution network continues to grow, that goal is becoming more and more a reality," noted Rock Rutherford, the CEO of AGR Stone & Tools USA, Inc.

About AGR Stone & Tools USA, Inc.

--------------------------------- AGR Stone & Tools USA, Inc. is a major supplier of diamond tools and adhesives. It specializes in producing consumable tools for the natural stone, engineered stone, concrete and masonry industries. Its goal is to provide its clients with superior quality products, excellent customer service and the most competitive prices in the diamond tool industry. The company has completed extensive research and testing, and uses the latest technologies to assure AGR Tools is at the forefront of the diamond tool industry. The company employs some of the world's top scientists, engineers and metallurgists to produce the highest quality diamond tools for the construction industry.

On October 29, 2009, AGR Tools, Inc. and AGR Stone & Tools USA, Inc. entered into a binding share exchange agreement. See AGR Tools, Inc.'s Current Report on Form 8-K filed on November 2, 2009 regarding the new share exchange agreement with AGR Stone & Tools USA, Inc. for details on various conditions which must be met before the share exchange between the two companies closes. There can be no assurance that the share exchange will close. AGR Tools, Inc must issue 46,186,516 shares of its common stock to the current shareholders of AGR Stone & Tools USA, Inc. in order to complete the share exchange. Accounting for the anticipated cancellation of 25,000,000 shares of its common stock, upon the closing of the share exchange AGR Tools, Inc. will have 81,186,516 shares of common stock issued and outstanding.

More information on AGR Stone & Tools USA, Inc. can be found at: www.agrtools.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: AVII - AVI BioPharma, Inc.) LATEST NEWS!! Systemic Treatment With AVI-4658 Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne Muscular Dystrophy Patients Positive RNA and Protein Signals in First Cohorts Analyzed; Conference Call Scheduled Today at 8:30 AM Eastern Time BOTHELL, WA, Dec 22, 2009 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced initial efficacy data from the ongoing Phase 1b/2 clinical trial of AVI-4658 for the systemic treatment of patients with Duchenne muscular dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin. Patients in the first four (of six) cohorts completing 12 weeks of treatment with different doses of AVI-4658 (0.5, 1.0, 2.0 or 4.0 mg/kg) have had their muscles biopsied. Analysis of the post treatment biopsies found that patients in the 2 and 4 mg/kg drug-treatment cohorts (3 of 3 in total) showed correctly spliced mRNA for dystrophin. One of these patients, in the 2mg/kg cohort, showed robust expression of dystrophin protein by western blot and immunofluorescent analysis. No RNA or protein expression signal was detected in patients from the 0.5 mg/kg or 1.0 mg/kg cohorts after completing treatment. Restoration of functional dystrophin expression is considered critical for successful treatment of DMD.

Treatment with AVI-4658 in the three patients in the 2.0 and 4.0 mg/kg cohorts led to accurate skipping of exon 51, which is believed to be necessary to restore the mRNA reading frame for functional dystrophin expression in patients with this class of mutations. Analysis of post-treatment biopsies by the reverse transcription-polymerase chain reaction showed a new lower molecular weight band of RNA resulting from the intended skipping, or exclusion, of exon 51. The intensity of the higher molecular weight band (which included exon 51) was correspondingly reduced. In one of the patients at the 2.0 mg/kg dose, the appearance of skipped mRNA was accompanied by a robust increase in expression of dystrophin protein in the post treatment samples using both western blot and immunofluorescent analysis. Western blot analysis detected a fivefold increase in dystrophin expression, from 0.9% to 5.3% of normal. Immunofluorescent analysis of the muscle biopsies from this patient showed an increase in the percentage of dystrophin positive muscle fibers from 1% pre-treatment to 21% in the post-treatment biopsy. Quantitative intensity analysis of the amount of dystrophin per fiber in patient samples before and after drug treatment showed a sevenfold increase in dystrophin. When compared to the level of dystrophin in normal muscle fibers, the dystrophin content per patient fiber went from 5% pre-treatment to 37% in the post-treatment biopsy.

"I am very encouraged by the evidence of accurate skipping of exon 51 in three treated patients," stated Prof. Francesco Muntoni, Professor of Pediatric Neurology and Head of the Dubowitz Neuromuscular Centre at the UCL Institute of Child Health, London, England and the trial's lead investigator. "These results suggest that we are on the right path towards developing a drug that could play a role in the treatment of DMD. The fact that one patient at the 2 mg/kg dose showed significant expression of dystrophin protein leads us to expect greater levels of dystrophin expression following treatment with the higher doses of 10.0 mg/kg and 20.0 mg/kg of AVI-4658, which are currently underway in the trial." Clinical Trial Design and Update Study 28 is a Phase 1b/2 open label, dose-ranging clinical trial assessing the safety, tolerability, pharmacokinetics and exploratory efficacy of AVI-4658 in ambulatory DMD boys between the ages of 5 and 15 years of age who have an error in the gene coding for dystrophin that could be treated by skipping exon 51. Patients are dosed once per week for 12 weeks by intravenous infusion. Nineteen patients have been enrolled in total and assigned to one of six dose cohorts: 0.5, 1.0, 2.0, 4.0, 10.0 or 20.0 mg/kg. After completion of dosing, patients are followed for a further 14 weeks. The primary objective of the trial is to assess the safety of AVI-4658 at these doses over the 26-week duration of the trial.

To date, 9 of 10 patients in the first four cohorts (0.5 through 4.0 mg/kg) have completed dosing. A single patient (in the 4 mg/kg cohort) withdrew from treatment due to DMD-related cardiomyopathy (now stabilized and believed not to be drug related). An additional patient was enrolled at 4 mg/kg but has not yet completed dosing. All 8 patients in the fifth and sixth cohorts, receiving 10 or 20 mg/kg respectively, have initiated dosing.

Data from patients dosed to date demonstrate that AVI-4658 continues to be generally very well tolerated. Adverse events reported to date are mostly mild, unrelated to drug treatment and transient. In the patients who completed dosing, two serious adverse events, both deemed unrelated to AVI-4658, were reported in different patients after they completed their 12-week treatment period and during the 14-week follow-up period.

Studies Towards US IND AVI has completed a series of 12-week preclinical studies of AVI-4658 under Good Laboratory Practice (GLP) conditions required to open an Investigational New Drug (IND) application in the US. The studies tested doses up to 960 mg/kg in both mdx and wild type mice, and up to 320 mg/kg in non-human primates, both doses being the maximum feasible single doses in these animals. In all cases the PMO was well tolerated at doses equivalent to 80 mg/kg and 110 mg/kg in humans respectively (based on standard allometric scaling), suggesting the potential for a wide therapeutic index.

An additional GLP study of AVI-4225 PMO, to skip exon 23, in the mdx mouse has also been completed, with similar encouraging reports of good tolerability. The histopathology is currently being reviewed but initial reports suggest that the muscles of treated mice show improvement over the 12 weeks of study.

"AVI-4658 continues to demonstrate the good safety profile associated with PMO-based drug candidates. Data from the recently completed series of preclinical studies required to open an IND in the US suggest that this good tolerability is likely to continue at higher doses," stated Stephen B. Shrewsbury, M.D., Senior Vice President and Chief Medical Officer, AVI BioPharma, Inc. "This is critically important given that any DMD drug based on exon skipping is expected to be administered regularly over the entire course of a patient's life." The clinical trial of AVI-4658 is being conducted in London, UK at the UCL Institute of Child Health / Great Ormond Street Hospital NHS Trust facilities by members of the MDEX Consortium led by Professor Muntoni and by Professor Kate Bushby at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the coordinating center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.

About Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy (DMD) is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with DMD with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing requiring ventilatory support. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time ever, there are promising therapies in or moving into development.

Conference Call AVI management will hold a conference call to review the initial data from the ongoing Phase 1b/2 clinical trial on Tuesday, December 22, 2009, at 8:30 AM Eastern time (5:30 AM Pacific Time).

Individuals interested in listening to the live conference call may do so by dialing 877-879-6209 toll free within the United States and Canada, or 719-325-4794 for international callers. A replay of the call will be available by dialing 888-203-1112 toll free within the United States and Canada, or 719-457-0820 for international callers. The passcode for the replay is 1823048. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.

About AVI BioPharma AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junin, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: PRGS - Progress Software Corp.) LATEST NEWS!! Progress Software Announces 2009 Fourth Quarter Results Earnings Up in Q4; Progress Actional Revenue Up with Triple-Digit Growth; Progress(R) Apama(R) Revenue Up with Double-Digit Growth BEDFORD, Mass., Dec 22, 2009 -- Progress Software Corporation (NASDAQ:PRGS), a leading independent enterprise software provider that enables companies to be operationally responsive, today announced results for its fourth quarter ending November 30, 2009. On a generally accepted accounting principles (GAAP) basis, revenue for the quarter was $136.8 million, down 2 percent (5 percent at constant currency) from $139.4 million in the fourth quarter of fiscal 2008. On a non-GAAP basis, revenue totaled $136.9 million, representing a 4 percent decrease (7 percent at constant currency) over the year ago period. Software license revenue decreased 7 percent (10 percent at constant currency) to $52.0 million from $56.1 million in the same quarter last year.

On a GAAP basis, operating income increased 202 percent to $25.8 million from $8.5 million in the fourth quarter of fiscal 2008. Net income increased 158 percent to $16.7 million from $6.5 million in the same quarter last year. Diluted earnings per share increased 150 percent to 40 cents from 16 cents in the fourth quarter of fiscal 2008.

On a non-GAAP basis, operating income increased 10 percent to $37.4 million from $34.0 million in the same quarter last year. Non-GAAP net income increased 7 percent to $25.6 million from $24.0 million in the same quarter last year and non-GAAP diluted earnings per share increased 5 percent to 61 cents per share from 58 cents in the fourth quarter of fiscal 2008.

For the twelve months ended November 30, 2009, GAAP revenue decreased 4 percent (up 1 percent at constant currency) to $494.1 million from $515.6 million in fiscal 2008. On a non-GAAP basis, revenue decreased 4 percent (up 1 percent at constant currency) to $496.8 million from $518.3 million in fiscal 2008.

On a GAAP basis, operating income decreased 21 percent to $51.1 million from $64.4 million in fiscal 2008. Net income decreased 29 percent to $32.8 million from $46.3 million in fiscal 2008 and diluted earnings per share decreased 26 percent to 80 cents from $1.08 in fiscal 2008.

On a non-GAAP basis, operating income decreased 6 percent to $109.4 million from $115.9 million last year. Non-GAAP net income decreased 10 percent to $73.8 million from $81.9 million last year and non-GAAP diluted earnings per share decreased 6 percent to $1.80 from $1.92 in fiscal 2008.

Non-GAAP amounts exclude the amortization of acquired intangibles, stock-based compensation, restructuring and acquisition-related costs, purchase accounting adjustments for deferred revenue and professional services fees associated with the investigation and shareholder derivative lawsuits related to the company's historical stock option grant practices.

The non-GAAP results noted above and the non-GAAP financial outlook for 2010 discussed below represent non-GAAP financial measures. A reconciliation of these measures to the appropriate GAAP measures for the three and twelve months ended November 30, 2009 and 2008 and the 2010 outlook, as well as further information regarding these measures, is included in the condensed financial information provided with this release.

The company's cash and short-term investments at the end of the year totaled $224.1 million.

In September 2009, Progress Software's Board of Directors extended the company's stock repurchase program by authorizing Progress Software to repurchase an aggregate of 1 million shares during the period from October 1, 2009 until September 30, 2010. The company repurchased approximately 3,000 shares of its common stock at a cost of $0.1 million in the fourth quarter of fiscal 2009 under this new repurchase authorization.

Richard D. Reidy, president and chief executive officer, Progress Software, said: "We exceeded our guidance for both revenue and earnings in our fiscal fourth quarter as a result of excellent customer wins along with well-managed expense management, despite the difficult economic environment. The Progress Apama and Actional product lines achieved double- and triple-digit growth respectively in the fiscal fourth quarter. Furthermore, we expect our newer product lines to continue on their significant growth path in 2010 achieving a greater than 20 percent increase in revenue; we also anticipate strong earnings overall for the year." Q4 Highlights -- Progress Software announced that the Progress(R) Sonic ESB(R) (enterprise service bus) is deployed and operational at British Airport Authority's (BAA) Heathrow Airport Terminal 5. The Progress solution enables BAA to provide airport integration capabilities using the Sonic ESB product. This includes the creation of reusable integration services for new Terminal 5 systems and of specialist adaptors for the integration of existing key operational BAA systems, such as the Airport Operational Database Integration (http://tinyurl.com/ProgressBAA).

-- Progress Software has successfully enabled more than 250 Independent Software Vendors (ISVs) to deploy thousands of on-demand, SaaS applications over the past five years. These ISVs use the Progress OpenEdge(R) SaaS platform to build applications that are used in some of the most demanding and diverse business environments in the world (http://tinyurl.com/ProgressSaaS).

-- British Airways selected Progress Software SOA Solutions to upgrade their travel experience. The UK's largest international airline, British Airways (BA), will use the Progress portfolio of SOA solutions as a key part of its travel program to upgrade its IT systems by integrating over 600 different electronic systems and processes involved in getting BA passengers in the air. The flexibility of the Progress SOA portfolio allows BA to extend the features of its e-commerce site right through to its airports, by allowing greater self-service functionality and 'plug and play' capability (http://tinyurl.com/ProgressBritishAirways).

-- match2blue stands out from the crowd with the Progress Apama(R) Business Event Processing (BEP) platform by adding real-time capability to next-generation social networking. Enterprise platform enabler for mobile solutions, match2blue (www.match2blue.com), has selected the Apama platform to empower its social networking platform with real-time information on location, ideas, news and trends. The Apama BEP platform will form a crucial part of match2blue's back-end infrastructure, providing the performance and scalability needed, as well as supporting its business partners, who will be operating the location-based services to control and monitor their operations through dashboards (http://tinyurl.com/ProgressMatch2Blue).

-- Alphameric Solutions Ltd, the leading solutions provider to the gaming industry, selected the Progress Sonic ESB to revolutionize the way it handles content and messages across its network. Relying on highly complex and automated processes to deliver odds, prices, race information and documents across a distributed architecture -- most needing to be handled in a sub-hundred millisecond timeframe -- Alphameric needed a simpler way to incorporate new or updated information in real-time (http://tinyurl.com/ProgressAlphameric).

-- West Bend Mutual Insurance Company has selected the Progress Sonic ESB (enterprise service bus) and Progress Actional products to underpin a service-oriented architecture (SOA) based IT infrastructure. West Bend Mutual Insurance, a property and casualty insurance carrier, is pulling together dozens of disparate internal policy administration applications into a single integrated insurance portal (http://tinyurl.com/ProgressWestBend).

-- Progress Software announced the availability of the Progress Apama 4.2 Event Processing Platform. The Apama 4.2 release extends the capabilities of the previously announced Apama Parallel Correlator, and introduces significant new developer productivity features that accelerate the deployment of event processing applications. The Apama Parallel Correlator leverages multi-core, multi-processor hardware to deliver high throughput, low latency execution that has achieved seven-fold performance improvements, as benchmarked with real-world customer applications (http://tinyurl.com/ProgressApama4-2).

-- Slumberland, a leading furniture retailer, is now using standards-based data connectivity products from Progress DataDirect(R) for reliable, high-performance support for all their major databases and 64-bit operating systems, for reliable connectivity to their Oracle applications, and streamlined reporting to improve fulfillment and customer satisfaction http://tinyurl.com/SlumberlandDataDirect).

-- Progress unveiled the industry's first mainframe SQL engine for non-relational data, which can leverage zIIP specialty processors for lowering a mainframe's total cost of ownership (TCO), with the announcement of its DataDirect Shadow(R) Release 7.2.1. The DataDirect Shadow release includes ANSI SQL-92 to Non-Relational Data with zIIP Offload and new capabilities that lower costs and attract new process-intense workloads to the mainframe (http://preview.tinyurl.com/DataDirectShadow7-2-1).

Business Outlook The company is providing the following guidance for the fiscal year ending November 30, 2010: -- Revenue, on a GAAP and non-GAAP basis, is expected to be in the range of $520 million to $530 million.

-- GAAP diluted earnings per share are expected to be in the range of $1.00 to $1.25.

-- On a non-GAAP basis, diluted earnings per share are expected to be in the range of $2.15 to $2.25.

The company is providing the following guidance for the first fiscal quarter ending February 28, 2010: -- Revenue, on a GAAP and non-GAAP basis, is expected to be in the range of $123 million to $126 million.

-- GAAP diluted earnings per share are expected to be in the range of a loss of 18 cents to breakeven.

-- On a non-GAAP basis, diluted earnings per share are expected to be in the range of 44 cents to 46 cents.

The outlook for the non-GAAP amounts excludes amortization of acquired intangibles, stock-based compensation, restructuring charges and acquisition-related expenses. As previously announced, the company initiated a restructuring plan in the first quarter of fiscal 2010 that will result in a pre-tax charge of between $20 million and $30 million related to reductions in headcount and consolidation of facility locations.

Legal Notice Regarding Non-GAAP Financial Information The company provides non-GAAP revenue, operating income, net income and earnings per share as additional information for investors. These measures are not in accordance with, or an alternative to, generally accepted accounting principles in the United States (GAAP). Such measures are intended to supplement GAAP and may be different from non-GAAP measures used by other companies. The company believes that the non-GAAP results described in this release are useful for an understanding of its ongoing operations and provide additional detail and an alternative method of assessing its operating results. Management of the company uses these non-GAAP results to compare the company's performance to that of prior periods for analysis of trends and for budget and planning purposes. A reconciliation of non-GAAP adjustments to the company's GAAP financial results is included in the tables below.

Conference Call The Progress Software conference call to discuss its fiscal fourth quarter 2009 results and business outlook will be Webcast live today at 9:00 a.m. Eastern Daylight Time on the company's Web site, located at www.progress.com/investors. The call will also be Webcast live via Yahoo (www.yahoo.com), Motley Fool (www.fool.com), Streetevents (www.streetevents.com), TD Waterhouse (www.tdwaterhouse.com) and Fidelity.com (www.fidelity.com). An archived version of the conference call will be available for replay on the Progress website (www.progress.com), together with the slide presentation for the call, under the investor relations page.

Progress Software Corporation Progress Software Corporation (NASDAQ: PRGS) is a global software company that enables enterprises to be operationally responsive to changing conditions and customer interactions as they occur -- to capitalize on new opportunities, drive greater efficiencies and reduce risk. The company offers a comprehensive portfolio of best-in-class infrastructure software spanning event-driven visibility and real-time response, open integration, data access and integration, and application development and deployment -- all supporting on-premises and SaaS/Cloud deployments. Progress maximizes the benefits of operational responsiveness while minimizing IT complexity and total cost of ownership. Progress can be reached at www.progress.com or +1-781-280-4000.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: LIFE - Life Technologies Corporation) LATEST NEWS!! Life Technologies to Present at the 28th Annual J.P. Morgan Healthcare Conference CARLSBAD, Calif., Dec 22, 2009 -- Life Technologies Corporation (NASDAQ:LIFE) today announced it will present at the 28th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, at 7:30 a.m. PST at the St. Francis Westin Hotel in San Francisco. Greg Lucier, Life Technologies' Chairman and Chief Executive Officer, will present on behalf of the company. The company will webcast the presentation, which will be available on the Life Technologies' investor relations website for 3 weeks following the conference.

About Life Technologies Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: CNQR - Concur Technologies, Inc.) LATEST NEWS!! Concur Surpasses 10,000 Client Mark --Strong demand for industry-leading Employee Spend Management solutions pushes client count over the 10,000 plateau as company heads into 2010 REDMOND, Wash., Dec 22, 2009 -- Concur (Nasdaq: CNQR), the world's leading provider of on-demand Employee Spend Management services, today announced a significant milestone as the company's client count reached the 10,000 plateau - a customer base that represents more than 10 million employees - during its recently completed fiscal 2009. Fueled by strong demand for its on-demand services, Concur saw its largest number of new customer additions in the fourth quarter of fiscal 2009, helping the company finish a strong fiscal year with a 15 percent year-over-year increase in revenue.

"Concur's mission has always focused on helping our clients drive costs out of their businesses. In an uncertain economy in which budgets are being slashed and operating costs are being scrutinized from every angle, the need for our Employee Spend Management services has never been greater," said Rajeev Singh, president and COO of Concur. "2009 saw the company deliver significant new innovations, expand our presence into new markets and continue to lead the way in delivering world-class on-demand services. As we head into 2010 and continue setting the pace of innovation in our industry, this milestone is both a direct reflection of the dedication and commitment of over 1200 Concur employees around the globe and a testament to the value that Concur delivers to each and every client." Recognized as a worldwide leader in Software-as-a-Service (SaaS), Concur's on-demand business solutions help organizations control costs by automating the entire corporate travel and expense reporting process, streamlining invoice processing, and helping to manage all associated business processes. Concur's suite of award-winning on-demand services - including Concur(R) Travel & Expense, Concur(R) Cliqbook Travel, Concur(R) Expense, Concur(R) Invoice, Concur(R) Intelligence, Concur(R) Advantage - all allow companies to get up and running quickly so they can focus on what's most important. By automating and optimizing business processes, Concur's services help drive down costs, ensure compliance and deliver actionable business intelligence.

About Concur Concur is the world's leading provider of on-demand Employee Spend Management services. Trusted by thousands of organizations to reach millions of employees, Concur's award-winning solutions streamline business travel and expense reporting, and improve invoice processing - delivering rapid ROI by helping companies increase efficiency, control employee spend and drive down operational costs. Learn more at www.concur.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: MYL - Mylan, Inc.) LATEST NEWS!! Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication --Expects to qualify for 180 days of sole marketing exclusivity PITTSBURGH, Dec 22, 2009 -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Schering Corporation and MSP Singapore Company in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg. This product is the generic version of Vytorin(R) Tablets, a cholesterol treatment.

Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for the product and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Schering and MSP Singapore filed a lawsuit Dec. 16 in the U.S. District Court for the District of New Jersey alleging patent infringement.

Vytorin Tablets had approximately $1.6 billion in sales for the same strengths for the 12 months ending Sept. 30, according to IMS Health. Currently, Mylan has 133 ANDAs pending FDA approval representing $85.6 billion in annual brand sales, according to IMS. Thirty-eight of these pending ANDAs are potential first-to-file opportunities, representing $19.3 billion in annual brand sales, according to IMS.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

((Comments on this story may be sent to info@m2.com)) (c) 2009 M2 COMMUNICATIONS

[ Back To Homepage ]